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Abstract
Background: Interferon lambda 3 (IFN-l3) is a newly identified cytokine with antiviral activity, and its single nucleotide
polymorphisms are strongly associated with the treatment effectiveness and development of chronic hepatitis C virus
infection. We thus examined the potential of IFN-l3 to inhibit HIV replication and the possible mechanisms of the anti-HIV
action by IFN-l3 in human macrophages.
Principal Findings: Under different conditions (before, during, and after HIV infection), IFN-l3 significantly inhibited viral
replication in macrophages, which was associated with the induction of multiple antiviral cellular factors (ISG56, MxA, OAS-
1, A3G/F and tetherin) and IFN regulatory factors (IRF-1, 3, 5, 7 and 9). This anti-HIV action of IFN-l3 could be compromised
by the JAK-STAT inhibitor. In addition, IFN-l3 treatment of macrophages induced the expression of toll-like receptor 3
(TLR3) and two key adaptors (MyD88 and TRIF) in type I IFN pathway activation. However, HIV infection compromised IFN-
l3-mediated induction of the key elements in JAK-STAT signaling pathway.
Conclusions: These data indicate that IFN-l3 exerts its anti-HIV function by activating JAK-STAT pathway-mediated innate
immunity in macrophages. Future in vivo studies are necessary in order to explore the potential for developing IFN-l3-
based therapy for HIV disease.
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Introduction
Interferon lambdas (IFN-ls) are a class of newly identified
members of IFN family. IFN-l subfamily is comprised of three
structurally related cytokines (IFN-l1, IFN-l2, IFN-l3), which are
also called interleukin-29 and interleukin-28A/B (IL-29, IL-28A,
IL-28B), respectively [1,2]. IFN-l could be activated following
viral infections or activation of toll-like receptors (TLRs) [3,4]. The
expression of IFN-l can induce antiviral factors to suppress the
replication of broad spectrum of viruses [4]. IFN-l functionally
resembles type I IFNs, inducing antiviral protection in vitro
[1,2,5,6] as well as in vivo [7]. However, unlike type I IFN
receptors that are broadly expressed on most cell types, including
cells in the brain, the expression pattern of the IFN-l receptors is
more cell-specific. Thus IFN-l has fewer side effects than IFN-a
[8], which is considered as a significant advantage over IFN-a.
IFN-l binds to its two receptors, which activates JAK-STAT
signaling pathway, resulting in the phosphorylation of STAT
proteins and forming of ISGF3 complex [9]. The formed ISGF3
complex binds to the IFN-stimulated response element (ISRE) and
induces host responses to viral infections [10]. The potential
clinical importance of IFN-l as a novel antiviral therapeutic agent
has recently become apparent. Several groups [11–14] reported
that the endogenous IFN-l system is associated with treatment-
induced clearance of hepatitis C virus (HCV). This finding has
further promoted interest in studying the antiviral mechanisms of
IFN-l, particularly IFN-l3.
Although it has been reported that two members of IFN-l
family, IFN-l1 and IFN-l2, could inhibit HIV replication in
macrophages [6], it is unclear, however, whether IFN-l3 possesses
the anti-HIV function as well. In this study, we examined whether
IFN-l3 has the antiviral ability against HIV infection of
macrophages. We also examined the mechanisms involved in
IFN-l3-mediated actions against HIV.
Materials and Methods
Cells and viruses
Peripheral blood samples were obtained from healthy donors
and tested for HIV antibody. The Institutional Review Board of
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informed consents were obtained from all the subjects. All
investigations have been conducted according to the principles
expressed in the Declaration of Helsinki. PBMCs were isolated
by Ficoll gradient, and further incubated with Dulbecco’s
modified Eagle medium (DMEM) in gelatin-coated flasks for
4 5m i ni n3 7 uC to collect monocytes. After detachment with
10 mM EDTA, monocytes were washed with DMEM and
resuspended in 10% DMEM including 10% fetal bovine serum,
glutamine (2 mmol/ml), penicillin (100 U/ml), streptomycin
(100 mg/ml), and nonessential amino acids. Monocytes purifica-
tion were determined by nonspecific esterase staining and
fluorescence-activated cell sorting analysis with a monoclonal
antibody against CD14 (Leu-M3) and low-density lipoprotein
specific for monocytes and macrophages [6]. Monocytes were
seeded in 96-well-plate (10
5 cells/well), or 48-well-plate (2.5610
5
cells/well), and differentiated to macrophages after cultured for 7
days. HIV Bal strain (R5) was obtained from the AIDS Research
and Reference Reagent Program, National Institutes of Health
(Bethesda, MD).
Reagents
Recombinant human IFN-l1 and IFN-l2 were purchased from
PeproTech Inc. (Rocky Hill, NJ). Recombinant human IFN-l3
was purchased from R&D Systems, Inc. (Minneapolis, MN), the
purity of IFN-l3 is similar to that of IFN-l1 and IFN-l2. JAK
inhibitor I was purchased from EMD Chemicals, Inc. (Gibbstown,
NJ), and dissolved in 1% dimethyl sufoxide (DMSO). HIV p24
monoclonal antibody was obtained from NIH AIDA Research &
Reference Reagent Program.
HIV infection and IFN-l treatment
Seven-day-cultured macrophages were incubated with IFN-l
either 24 h prior to HIV Bal infection, or simultaneously with
HIV infection, or 4 days after HIV infection. The productive HIV
infection was determined at day 12 postinfection. In the
experiments where the dose and time effects of IFN-l3 were
examined, IFN-l3 was added to the cultures 4 days postinfection
and continuously presented in the cultures. In order to determine
the role of JAK-STAT pathway in the IFN-l3 action against HIV,
JAK inhibitor I was added to cell culture 1 h prior to IFN-l3
treatment.
Reverse transcriptase (RT) activity assay
HIV RT activity was determined with the technique of Willey et
al. [15] with some modifications [6,16]. Briefly, 10 mlo f
supernatant collected from HIV-infected macrophages cultures
were added to 50 ml of cocktail containing poly (A), oligo (dT),
MgCl2, Nonidet P-40, and [
32P] dTTP and incubated overnight at
37uC. Thirty microliters of the reaction mixture was spotted on
DE 81 paper and air dried. The filters were then washed for four
times in fresh standard saline citrate (SSC, contained with
0.3 mol/liter NaCl, 0.03 mol/liter sodium citrate, PH 7) and
100% ethanol. After dried, the filters were placed into the
scintillation vials and measured for radioactivity by liquid
scintillation analyzer (PerkinElmer Tri-Carb 2810TR, Downers
Grove, IL60515, USA).
RNA extraction and real-time RT-PCR
Total cellular nucleotide was extracted from macrophages using
TRIH Reagent (SIGMA-ALDRICH, Inc. St. Louis, MO 63178,
USA) as described previously [6]. Total RNA (1 mg) was subjected
Table 1. Primers for Real-time PCR.
Primer Sense Antisense
GAPDH 59-GGTGGTCTCCTCTGACTTCAACA-39 59-GTTGCTGTAGCCAAATTCGTTGT-39
TLR-3 59-AGCCACCTGAAGTTGACTCAGG-39 59-CAGTCAAATTCGTGCAGAAGGC-39
TLR-7 59-AAAATGGTGTTTCCAATGTGG-39 59-GGCAGAGTTTTAGGAAACCATC-39
TLR-9 59-TACCAACATCCTGATGCTAGACTC-39 59-TAGGACAACAGCAGATACTCCAGG-39
IRF-1 59-TGAAGCTACAACAGATGAGG-39 59-AGTAGGTACCCCTTCCCATC-39
IRF-3 59-ACCAGCCGTGGACCAAGAG-39 59-TACCAAGGCCCTGAGGCAC-39
IRF-5 59-AAGCCGATCCGGCCAA-39 59-GGAAGTCCCGGCTCTTGTTAA-39
IRF-7 59-TGGTCCTGGTGAAGCTGGAA-39 59-GATGTCGTCATAGAGGCTGTTGG-39
IRF-9 59-GCATCAGGCAGGGCACGCTGCACC-39 59-GCCTGCATGTTTCCAGGGAATCCG-39
MyD88 59-GCACATGGGCACATACAGAC-39 59-TGGGTCCTTTCCAGAGTTTG-39
TRIF 59-CTCACCTGACCCCCTCCT-39 59-AATTTCTGTTCCGATGATGATTC-39
STAT-1 59-GTGGAAAGACAGCCCTGCAT-39 59-ACTGGACCCCTGTCTTCAAGAC-39
STAT-2 59-CCCCATCGACCCCTCATC-39 59-GAGTCTCACCAGCAGCCTTGT-39
IL-28Ra 59-ACCTATTTTGTGGCCTATCAGAGCT-39 59-CGGCTCCACTTCAAAAAGGTAAT-39
IL-10Rb 59-GGCTGAATTTGCAGATGAGCA-39 59-GAAGACCGAGGCCATGAGG-39
ISG-56 59-TTCGGAGAAAGGCATTAGA-39 59-TCCAGGGCTTCATTCATAT-39
MxA 59-GCCGGCTGTGGATATGCTA-39 59-TTTATCGAAACATCTGTGAAAGCAA-39
OAS-1 59-AGAAGGCAGCTCACGAAACC-39 59-CCACCACCCAAGTTTCCTGTA-39
A3G 59-TCAGAGGACGGCATGAGACTTAC-39 59-AGCAGGACCCAGGTGTCATTG-39
A3F 59-TTCGAGGCCAGGTGTATTCC-39 59-GGCAGCTGGTTGCCACAGA-39
Tetherin 59-AAGAAAGTGGAGGAGCTTGAGG-39 59-CCTGGTTTTCTCTTCTCAGTCG-39
doi:10.1371/journal.pone.0035902.t001
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35902Figure 1. Effect of IFN-l3 on HIV infection of human macrophages. A. Dose-dependent effect of IFN-l3 on HIV infection. Seven-day-cultured
macrophages were infected with HIV Bal strain for 4 days, and then treated with IFN-l3 at indicated concentrations. HIV RT activity in supernatant
was analyzed at day 12 postinfection. B. Time-dependent effect of IFN-l3 on HIV infection. Seven-day-cultured macrophages were infected with HIV
Bal strain for 4 days and then treated with IFN-l3 at concentration of 100 ng/ml. HIV RT activity in the supernatant at indicated time point was
examined. C. Effect of IFN-l3 on HIV infection and replication under four different conditions. Macrophages were pre-treated with IFN-l3 (100 ng/ml)
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Madison, WI) for 1 h at 42uC. The resulting cDNA was used as a
template for real-time PCR quantification. Using the iQ SYBR
Green supermix (Bio-Rad Laboratories, Hercules, California),
messenger RNAs (mRNAs) in macrophages were detected for
antiviral factors (interferon-stimulated gene 56 (ISG-56), myxovi-
rus resistance-1 (MxA), obstructive sleep apnoea-1 (OAS-1),
APOBEC3G/APOBEC3F (A3G/F), tetherin, IFN regulatory
factor (IRF)-1, IRF-3, IRF-5, IRF-7, IRF-9, toll-like receptor
(TLR)-3, TLR-7, TLR-9, IFN-l3 receptors (IL-28Ra, IL-10Rb),
IFN-l3 signal pathway cytokines (Myeloid differentiation primary
response gene 88 (MyD88), TIR-domain-containing adapter-
inducing interferon-b (TRIF), signal transducer and activator of
transcription (STAT-1/2)) and glyceraldehydes 3-phosphate
dehydrogenase (GAPDH). The primers used for the parameters
above were listed in Table 1. The levels of GAPDH mRNA were
used as an endogenous reference to normalize the quantities of
target mRNA and presented as the change in induction relative to
that of untreated control cells.
Indirect immunofluorescence assay for HIV p24
HIV Bal-infected macrophages treated with or without IFN-l3
were washed with phosphate-buffered saline (PBS) and fixed in 4%
paraformaldehyde (EM Science) for 20 min at room temperature.
The cells were then permeabilized with 0.2% Triton for 10 min,
and blocked in blocking solution (10% fetal calf serum, 1%
penicillin/streptomylin, and 0.05% sodium azide in MEM) for
1 h. HIV p24 antigen was detected using mouse monoclonal anti-
HIV-p24 antibody and goat-anti mouse antibody conjugated with
Alexa Fluor 488 (Invitrogen). The cell nuclei were counterstained
with Hoechst dye. Microscopic analysis was performed with a
fluorescence microscope (Olympus).
Statistical analysis
Where appropriate, data were expressed as means 6 standard
deviations (SD) of at least three samples replicates. Data analysis
was performed using a 2-tailed Student’s t-test. Statistical analyses
were performed with Graphpad Instat Statistical Software
(Graphpad Software Inc., San Diego, CA), and the statistical
significance was defined as P,0.05.
Results
IFN-l3 inhibits HIV replication in macrophages
We first examined the effect of IFN-l3 on HIV replication in
macrophages. When added to HIV-infected macrophage cultures,
IFN-l3 significantly inhibited HIV RT activity in a dose (Fig. 1A)
and time (Fig. 1B) dependant fashion. This inhibitory effect of
IFN-l3 on HIV was observed under three different treatment
conditions (Fig. 1C). The highest inhibition of HIV was observed
in macrophage cultures pretreated with IFN-l3 (prior to HIV
infection) (Fig. 1C). To maintain IFN-l3 in HIV-infected cell
cultures was necessary, as the withdrawal of IFN-l3 from infected
cultures resulted in a viral rebound (Fig. 1C). HIV inhibition by
IFN-l3 was also confirmed by indirect immunofluorescence
staining with antibody against HIV p24 antigen (Fig. 2).
for 24 h, and then infected with HIV Bal strain (Before), or co-incubated with IFN-l3 (100 ng/ml) and HIV Bal strain at the same time (During), or 4
days after HIV infection, macrophages under the conditions above were treated with IFN-l3 (100 ng/ml) with or without IFN-l3 withdrawal. The
levels of HIV RT activity in supernatant were analyzed at day 12 postinfection. The data shown were the mean 6 standard deviation of triplicate
culture, and expressed as % of control (without IFN-l3 treatment, the mean value of which is defined as 100) (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0035902.g001
Figure 2. Indirect immunofluorescence assay for HIV p24. Seven-day-cultured macrophages were infected with or without HIV Bal strain for
2 h and cultured for 12 days in the presence or absence of IFN-l3 (100 ng/ml). Cells were then washed and fixed in 4% paraformaldehyde fixative and
treated with 0.2% triton. HIV p24 in infected macrophages was stained by HIV p24 antiserum (green color) and cell nuclei was stained by Hoechst and
observed through fluorescence microscope. (NC, Negative Control; PC, Positive Control).
doi:10.1371/journal.pone.0035902.g002
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To determine the mechanism of IFN-l3-mediated anti-HIV
activity in macrophages, we examined the effect of IFN-l3 on the
expression of TLRs as well as several key elements in IFN-l
signaling pathway in both uninfected and infected macrophages.
We first determined whether IFN-l3 treatment modulates TLR
(TLR3, 7, 9) expression in macrophages. IFN-l3 treatment of
uninfected macrophages could induce the expression of TLR7 and
TLR9 (Fig. 3A). More significantly, IFN-l3 induced TLR3
expression in uninfected macrophages as much as 40 folds
(Fig. 3A). We next examined whether IFN-l3 upregulates the
expression of IFN regulatory factors (IRFs). As shown in Fig. 3B,
IFN-l3 induced the expression of several key IRFs, particularly
IRF7 in uninfected macrophages (Fig. 3B). Because IFN-l,
through binding to IL-28Ra and IL-10Rb, activates JAK-STAT
pathway [17], and TLR activation induces type I IFN expressions
[18], we further examined the impact of IFN-l3 on type I IFN
signaling pathway. As shown in Fig. 3C, the expression of IL-28Ra
and STAT-1/2 was significantly induced by IFN-l3 in uninfected
macrophages. In addition, IFN-l3 treatment of uninfected
macrophages enhanced the expression of two key adaptors
(MyD88 and TRIF) in type I IFN pathway activation (Fig. 3C).
Because HIV infection/replication could have a negative effect on
the expression of the antiviral cellular factors, we examined the
impact of HIV on IFN-l3-mediated induction of the key elements
in JAK-STAT pathway in infected macrophages. As shown in
Fig. 4, although IFN-l could induce the expression of TLRs as
well as other antiviral factors in infected macrophages, the degree
of the induction was lower (Fig. 4) than that in uninfected cells
(Fig. 3).
IFN-l3 is more potent in suppressing HIV than IFN-l1
and IFN-l2
IFN-l1 or IFN-l2 has been shown to inhibit HIV replication in
macrophages [6], we thus compared the anti-HIV ability of IFN-
l3 with IFN-l1 or IFN-l2. As shown in Fig. 5A, the inhibitory
effect of IFN-l3 on HIV in macrophages is more potent than that
of IFN-l1 or IFN-l2. In addition, IFN-l3 was the most potent
inducer of cellular antiviral factors (ISG-56, MxA, OAS-1, A3G/F
and tetherin) among the three IFN-l family members (Fig. 5B).
The anti-HIV activity of IFN-l3 is dependent on JAK-STAT
pathway
In order to explore the mechanisms of the anti-HIV activity of
IFN-l3, we examined the role of JAK-STAT pathway in the IFN-
l3 action against HIV. As shown in Fig. 6A, the anti-HIV activity
of IFN-l3 was found to be significantly suppressed by the inhibitor
(JAK inhibitor I) of JAK-STAT pathway. In addition, JAK
inhibitor I treatment compromised the inducing effects of IFN-l3
on several key antiviral cellular factors, including ISG-56, MxA,
OAS-1, A3G/F and tetherin (Fig. 6B).
Discussion
Compared to IFN-l1 or IFN-l2, IFN-l3 is thought to be more
important for anti-HCV therapy, as its genetic variation of three
single-nucleotide polymorphisms (SNPs) (rs12979860, rs12980275,
and rs8099917) in upstream of the IFN-l3 (IL-28B) gene is highly
associated with treatment outcomes of Peg-IFNa-2a plus ribavirin
therapy [11–14]. Although the anti-HIV function of IFN-l1o r
IFN-l2 has been demonstrated [6], it remains to be determined
whether IFN-l3 has the ability to suppress HIV. In the present
study, we have provided the experimental evidence that similar to
IFN-l1 and IFN-l2, IFN-l3 treatment resulted in the inhibition
of HIV infection of macrophages. When macrophages were
pretreated once with IFN-l3, a nearly complete inhibition of HIV
of macrophages was observed (Fig. 1). The presence of IFN-l3i n
the cultures is necessary to maintain HIV suppression, as the
withdrawal of IFN-l3 from the cultures resulted in a rebound of
viral replication (Fig. 1C). This inhibitory effect of IFN-l3
treatment was seen even after HIV infection had been initiated
in macrophages (Fig. 1). We also demonstrated that IFN-l3
appeared to be more potent in inhibiting HIV replication in
macrophages than IFN-l1 or IFN-l2 (Fig. 5). This enhanced
ability to inhibit HIV could be due to its stronger effects on several
Figure 3. Effect of IFN-l3 on the key elements in JAK-STAT
pathway in uninfected macrophages. Seven-day-cultured macro-
phages were treated with or without IFN-l3 (100 ng/ml) for 24 h. Total
nucleotide were extracted from macrophages and subjected to the real-
time reverse transcription polymerase chain reaction (RT-PCR) assay for
mRNA expression of TLRs (A), IRFs (B) and the key elements in IFN-l3
signaling pathway (C). The data shown were the mean 6 standard
deviation of triplicate culture (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0035902.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35902Figure 4. Effect of IFN-l3 on the key elements in JAK-STAT pathway in HIV infected macrophages. Seven-day-cultured macrophages
were infected with HIV Bal strain for 2 h. IFN-l3 (100 ng/ml) was added to the cultures 4 days postinfection for 24 h. Total nucleotide were extracted
from macrophages and subjected to the real-time reverse transcription polymerase chain reaction (RT-PCR) assay for mRNA expression of TLRs (A),
IRFs (B) and the key elements in IFN-l3 signaling pathway (C). Seven-day-cultured macrophages neither infected with HIV Bal strain nor treated with
IFN-l3 were set as control for a fair comparison with that in Figure 3. The data shown were the mean 6 standard deviation of triplicate culture
(*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0035902.g004
IFN-l3 Inhibits HIV
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l2 (Fig. 5B).
IFN-l functionally resembles type I IFNs in antiviral protection
[19]. Despite of the overlapping antiviral functions of IFN-l with
type I IFNs, the more restriction pattern of IFN-l receptor (IL-
28Ra) expression suggests that IFN-l has a more specialized role
in host antiviral defense against viruses in a subset of cells [20,21].
In addition, the mechanisms by which IFN-l establishes an
antiviral state are not as well characterized as those for IFN-a/b.
Our studies showed that IFN-l3 through multiple mechanisms
suppressed HIV infection and replication. We first investigated
whether IFN-l3 activates JAK-STAT signaling pathway, inducing
the antiviral state in macrophages. IFN-l3 treatment of macro-
phages upregulated the expression of either key factors of JAK-
STAT pathway, such as STAT1 and STAT2 (Fig. 3C, 4C), or the
known ISGs in the downstream of JAK-SATA pathway, including
ISG-56, MxA, and OAS-1 (Fig. 5B). The role of JAK-STAT
pathway in the anti-HIV activity of IFN-l3 was further confirmed
by the observation that to block of JAK-STAT signaling pathway
by the JAK inhibitor could compromise the IFN-l3 action on
HIV and significantly decrease the expression of IFN-l3-induced
antiviral factors (Fig. 6). We also demonstrated that APOBEC3G
and APOBEC3F, the specific anti-HIV cellular factors, were
induced by IFN-l through JAK-STAT pathway (Figs. 5B and 6B).
In addition, tetherin, a transmembrane protein that specifically
inhibits HIV infection by preventing its release from infected cells,
was also induced by IFN-l through JAK-STAT pathway (Figs. 5B
and 6B). Thus, JAK-STAT pathway plays a crucial role in the
anti-HIV activity of IFN-l3 in macrophages, which is in
agreement with the previous findings, showing that IFN-l3,
through the activation of JAK-STAT pathway, exerts its anti-
HCV function in human hepatocytes [10].
Figure 5. Effects of IFN-l1, IFN-l2 and IFN-l3 on HIV. A. Seven-day-cultured macrophages were infected with HIV Bal strain for 4 days and
then treated with or without IFN-l1/2 (100 ng/ml) or IFN-l3 (100 ng/ml) for 8 days. HIV RT activity in the supernatant was analyzed at day 12
postinfection. The data were expressed as HIV RT levels relative (%) to control (without IFN-l treatment, which defined as 100). B. Seven-day-cultured
macrophages were treated with or without IFN-l1/2 (100 ng/ml) or IFN-l3 (100 ng/ml) for 24 h, and total nucleotide of macrophages was extracted
for real-time RT-PCR analysis of the mRNA expression of ISG-56, MxA, OAS-1, A3G/F, tetherin and GAPDH. The data were expressed as mRNA levels for
the anti-HIV factors relative (folds) to the control (without IFN-l treatment, which is defined as 1). (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0035902.g005
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because they recognize and respond to PAMPs, which leads to
activation of intracellular signaling pathways. Among the eleven
identified human TLRs, three TLRs (TLR- 3, 7, and 9) play a key
role in virus-mediated innate immunity, as they specifically
recognizes viral RNA or DNA and initiate antiviral signaling
pathways in macrophages [22,23]. Our studies demonstrated that
IFN-l3 could significantly induce the expression of TLR3 as well
as TLR3-associated adaptors such as MyD88 and TRIF (Figs. 3A,
3C, 4A and 4C). These observations provide an additional
mechanism for IFN-l3-mediated anti-HIV action, as TLR3
signaling has a crucial role in early innate immune response to
viral infections, including HIV [24].
Our further investigation showed that IFN-l3 induced the
expression of IRFs (IRF-1, 3, 5, 7 and 9) in macrophages infected
with or without HIV (Figs. 3B and 4B). The IRFs are important
regulators in the type I and III IFN-mediated antiviral immunity.
These regulators not only recognize the elements of DNA
promoter to modulate type I and III IFN genes, but also regulate
the IFN-stimulated response element (ISRE) in some of ISGs,
leading to induction of an antiviral state [25,26]. Recent studies
[27–29] have further demonstrated an essential role of IRF-3,
IRF-5, and IRF-7 in the activation of type I and III IFN
expression, which is critical for the production of down-stream
antiviral factors such as ISG-56, MxA, OAS-1, tetherin (Fig. 6).
Taken together, our data have provided the compelling
evidence that IFN-l3 through the activation of TLR3 and JAK-
STAT pathways inhibited HIV infection of macrophage. Al-
though the precise cellular and molecular mechanisms by which
IFN-l3 inhibits HIV replication remain to be determined, the
induction of multiple cellular restriction factors against HIV
should account for much of IFN-l3-mediated anti-HIV activity.
Figure 6. Effect of JAK-STAT inhibitor on the IFN-l3 actions. A. Effect of JAK-STAT inhibitor on the anti-HIV action of IFN-l3. Macrophages
were infected with HIV Bal strain for 4 days, and then incubated with JAK inhibitor I (1 mM) for 1 h prior to IFN-l3 (100 ng/ml) treatment. HIV RT
activity in supernatant was measured at day 12 postinfection. B. Effect of JAK-STAT inhibitor on IFN-l3-mediated induction of cellular antiviral factors.
Macrophages were incubated with JAK inhibitor (1 mM) for 1 h prior to IFN-l3 (100 ng/ml) treatment for 24 h. The expression of ISG-56, MxA, OAS-1,
A3G/F and tetherin was indicated as the increase in induction (folds) relative to without IFN-l3 treated cells, which is normalized to GAPDH levels.
Values were expressed as mean 6 standard deviation of triplicate culture (*P ,0.05, ** P,0.01).
doi:10.1371/journal.pone.0035902.g006
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35902These anti-HIV mechanisms of the IFN-l3 action offer an
attractive alternative for HIV treatment, as it would be extremely
difficult for HIV to develop resistance to the IFN-l3 actions that
suppress virus at various steps of its replication in the context of
host cell innate immunity. However, future studies are needed in
order to determine the impact of IFN-l3 on HIV in ex vivo and in
vivo systems. These additional studies shall explore the potential for
developing IFN-l3-based therapy for people infected with HIV.
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